![[AI Burst] Code That Cures Cancer](https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,quality=80,format=auto,width=720,onerror=redirect/uploads/asset/file/2e0db16e-dc51-424d-ba81-ad2f0aedaae7/Code_That_Cures_Cancer.png)
AI Insights in 4 Minutes from Global AI Thought Leader Mark Lynd
Welcome to another edition of the AI Bursts Newsletter. Let’s dive into the world of AI with an essential Burst of insight.
✨ THE BURST
A single, powerful AI idea, analyzed rapidly.
💡The Idea
While the internet argues about chatbots, the smart money has moved to "Generative Biology." At the J.P. Morgan Healthcare Conference this week, the buzz wasn't about generating text, but generating molecules. Startups like Kailera Therapeutics (raising $600M) are using diffusion models, which is the same tech behind Midjourney to hallucinate new protein structures that don't exist in nature but perfectly bind to disease targets.
❓Why It Matters
This is the shift from "Bits" to "Atoms." Traditional drug discovery is a lottery ticket: expensive, slow, and mostly fails. AI turns it into an engineering problem. We are moving from discovering drugs (finding what nature hid) to designing drugs (printing what we need). The value proposition here is infinite: curing obesity, cancer, and aging is worth more than a better search engine.
🚀 The Takeaway
Diversify your attention. If you are an investor or builder, look at the "TechBio" stack. The next trillion-dollar company won't be a social media app; it will be the company that creates the "Foundation Model for Biology."
🛠️ THE TOOLKIT
The high-leverage GenAI stack you need to know this week.
The Designer: Nvidia BioNeMo has updated its cloud service to include "ESM-3," a generative model that can simulate the evolution of proteins over 500 million years in seconds to find stable drug candidates.
The Lab: Benchling launches "Agentic R&D," a platform where AI agents can plan wet-lab experiments, analyze the data, and iterate on the hypothesis without human intervention.
The Simulator: Google DeepMind teases "AlphaFold 4," promising to not just predict protein structure, but to predict how those proteins interact with other molecules (ligands) with near-perfect accuracy.
Mark’s 30 AI Predictions for 2026 Based on Hundreds of Customer Interactions
📊 AI SIGNAL
Your 30-second scan of the AI landscape.
VC Funding: Kailera Therapeutics emerges from stealth with $400M in Series A funding, marking one of the largest biotech debuts in history, driven entirely by its AI-first discovery engine.
Scientific Breakthrough: Researchers at Washington State University use AI to discover a molecular "switch" that stops the Herpes virus from entering cells, a feat that eluded human scientists for decades.
Industry Pivot: Sanofi announces "AI at Scale," a commitment to becoming the first pharma company powered entirely by AI, deploying agents across R&D, manufacturing, and commercialization.
🧠 BYTE-SIZED FACT
It took 13 years and $2.7 billion to sequence the first human genome (The Human Genome Project, completed in 2003). Today, AI-powered sequencers can do it in a few hours for under $200.
🔊 DEEP QUOTE
"Biology is the only technology that can build a computer, run it on a burrito, and reproduce itself." — Unknown
Till next time,
For deep-dive analysis on cybersecurity and AI, check out my popular newsletter, The Cybervizer Newsletter
AI-native CRM
“When I first opened Attio, I instantly got the feeling this was the next generation of CRM.”
— Margaret Shen, Head of GTM at Modal
Attio is the AI-native CRM for modern teams. With automatic enrichment, call intelligence, AI agents, flexible workflows and more, Attio works for any business and only takes minutes to set up.
Join industry leaders like Granola, Taskrabbit, Flatfile and more.